bortezomib
takeda
['dlbcl', 'borte', ' abc,(- abcsg)', 'bortezomib']
andrew davies presents updated results from the remodl-b trial on addition of bortezomib to r-chop in pts with dlbcl. new high-molecular risk subgroup, along with abc group pts have improved pfs with bortezomib. os significant in abc, but not in hmg or gcb group #ash22 
The Lancet Haematology is a world-leading #haematology journal publishing peer-reviewed research and reviews, opinion, and news. #hematology